Our podcast on science and technology. We meet the immunologists searching for a jab to fight a wide range of pathogens https://t.co/TtxVmm4PDy ...

Core Insights - Novartis (NVS) has proposed the acquisition of Excellergy Inc. to enhance its immunology pipeline, focusing on food allergies and other IgE-mediated diseases [1][9] - The acquisition is valued at up to $2 billion, with expected closure in the second half of 2026, pending regulatory approvals [2] - Exl-111, a key asset in the acquisition, is a next-generation anti-IgE therapy in phase I development, which could expand Novartis' reach in treating various allergic conditions [3][9] Acquisition Details - The deal includes upfront and milestone payments, reinforcing Novartis' commitment to its allergy franchise [2][9] - Exl-111 aims to improve efficacy and dosing convenience, potentially addressing high-value indications such as food allergies and chronic urticaria [3] Strategic Alignment - The acquisition aligns with Novartis' broader immunology ambitions and leverages its expertise in IgE biology, complementing its existing allergy portfolio, which includes Xolair [4] - Novartis is also evaluating remibrutinib for food allergies, further diversifying its treatment options in this area [5] Recent M&A Activity - Novartis has been active in mergers and acquisitions, recently acquiring a PI3Kα inhibitor program from Synnovation Therapeutics, which aligns with its oncology strategy [6][7] - Earlier in the year, Novartis acquired Avidity Biosciences, enhancing its neuromuscular pipeline [8] Market Context - 2026 is a pivotal year for Novartis due to significant patent expirations, particularly for the cardiovascular drug Entresto [8] - Despite challenges from generic competition, Novartis is focusing on growth drivers such as Kisqali, Kesimpta, Pluvicto, and Scemblix to support revenue growth [10]

Core Insights - Gilead Sciences, Inc. (GILD) is enhancing its external innovation strategy through targeted acquisitions to diversify its pipeline beyond its leading HIV franchise [1] Group 1: Acquisitions and Strategic Moves - The acquisition of Ouro Medicines introduces OM336 (gamgertamig), a clinical-stage bispecific T-cell engager, to Gilead's inflammation portfolio, valued at $1.675 billion upfront with potential milestones of up to $500 million [2] - Gilead's acquisition of Arcellx for approximately $7.8 billion focuses on anitocabtagene autoleucel (anito-cel), a late-stage CAR-T therapy for relapsed or refractory multiple myeloma, with a U.S. regulatory decision expected by December 2026 [3] - The Arcellx deal allows Gilead to consolidate full economic rights to anito-cel, enhancing long-term margin potential and value capture by eliminating prior profit-sharing and royalty obligations [4] Group 2: Financial Implications and Market Position - These acquisitions indicate a strategic shift towards higher-growth therapeutic areas such as oncology and immunology, reducing reliance on HIV revenues from blockbuster products like Biktarvy and Descovy [5] - Management anticipates that the Arcellx transaction will be earnings accretive by 2028, reinforcing the long-term financial rationale for these acquisitions [5] Group 3: Competitive Landscape - Gilead faces increasing competition in the cell therapy segment, particularly from Bristol Myers (BMY) and Novartis (NVS), which have strong CAR-T therapy portfolios [6][7] - BMY's Breyanzi surpassed $1 billion in annualized sales in 2025, while NVS's Kymriah recorded sales of $381 million in 2025, down 14% from 2024 due to competitive pressures [8][9] Group 4: Stock Performance and Estimates - GILD shares have increased by 11.5% year to date, outperforming the industry growth of 1.6% [13] - GILD's shares currently trade at a price/earnings ratio of 15.4x forward earnings, higher than its mean of 11.37x but lower than the large-cap pharma industry average of 16.99x [14] - The bottom-line estimate for 2026 has risen to $8.66 from $8.63 over the past 30 days, while the estimate for 2027 has increased to $9.63 from $9.59 [15]

Core Insights - Novartis will present over 20 abstracts from its immunology portfolio at the American Academy of Dermatology (AAD) Annual Meeting, showcasing advancements in treatments for chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS) [1][2][3] Immunology Portfolio Highlights - New data on Rhapsido (remibrutinib) will be presented, focusing on early symptom improvement in CSU patients, with significant changes in daily itch and hives severity scores observed as early as week 1 [2][4] - Long-term efficacy data for Cosentyx (secukinumab) will be shared, reinforcing its continuous use in HS and psoriasis, including a matched adjusted indirect comparison of its safety and flare prevention against bimekizumab [4][5] Key Abstracts - Notable abstracts include: - "Early symptom improvement with remibrutinib in chronic spontaneous urticaria" (Abstract 71668) [3] - "Flare prevention and safety of secukinumab vs bimekizumab in hidradenitis suppurativa" (Abstract 76852) [5] - "Effectiveness of Secukinumab in Preventing Psoriatic Arthritis in Patients with Moderate to Severe Psoriasis" (Abstract 73859) [5] Commitment to Innovation - Novartis emphasizes its dedication to advancing science in immunology, aiming to provide relief for patients with autoimmune diseases through a robust pipeline and innovative treatments [6]

Core Insights - Curanex Pharmaceuticals Inc. has appointed Dr. Taku Kambayashi and Dr. Selvakumar Subbian to its Scientific Advisory Board, enhancing its expertise in immunology and infectious diseases, which aligns with the company's therapeutic focus and clinical development roadmap [1][9] Group 1: New Appointments - Dr. Taku Kambayashi is a Professor at the University of Pennsylvania with expertise in immune cell signal transduction pathways, focusing on therapies for autoimmune and inflammatory diseases [2][3] - Dr. Selvakumar Subbian is a Professor at Rutgers University with over 25 years of experience in microbial pathogenesis, particularly in pulmonary infectious diseases like tuberculosis and COVID-19 [5][6] Group 2: Research Contributions - Dr. Kambayashi's research includes TSLP-stimulated T cells and their implications for obesity-related disorders, as well as therapeutic manipulation of regulatory T cell homeostasis in diseases such as multiple sclerosis and diabetes [3][4] - Dr. Subbian's laboratory has developed rabbit models for studying tuberculosis, contributing to host-directed therapy that enhances antibiotic efficacy [6][8] Group 3: Company Overview - Curanex Pharmaceuticals is focused on developing botanical drugs for inflammatory diseases, with its lead candidate, Phyto-N, showing anti-inflammatory properties and a history of human use in China [10][11] - Phyto-N has been validated in animal models for six inflammatory diseases, with a primary focus on moderate to severe ulcerative colitis, and is preparing for an Investigational New Drug (IND) submission [11]

AbbVie FY Conference Summary Company Overview - **Company**: AbbVie (NYSE: ABBV) - **Date of Conference**: March 03, 2026 - **Key Management Present**: - Scott Rents, Executive Vice President and CFO - Jeff Stewart, Executive Vice President and Chief Commercial Officer - Roopal Thakkar, Executive Vice President, R&D, and CSO Core Industry Insights - **Immunology Trials**: AbbVie is successfully conducting immunology trials, unlike some competitors facing high placebo rates. The company attributes its success to high efficacy levels of its assets, such as HUMIRA, SKYRIZI, and RINVOQ [2][3] - **Clinical Trial Strategy**: AbbVie employs rigorous patient and endpoint selection, real-time data monitoring, and training for trial sites to ensure successful outcomes [4][5][6] Key Product Developments - **RINVOQ**: Demonstrated a doubling of response rates compared to HUMIRA in rheumatoid arthritis trials, indicating strong efficacy [5] - **SKYRIZI**: New subcutaneous induction trial for Crohn's disease showed higher efficacy than the IV version, with a 60% endoscopic response in treatment-naive patients [6] - **Lutikizumab**: Undergoing phase 3 trials for hidradenitis suppurativa (HS) with a focus on stringent endpoints to control placebo responses [7][9] Market Potential - **Hidradenitis Suppurativa**: Identified as an under-penetrated market with significant growth potential, similar to inflammatory bowel disease (IBD) [13] - **Long-term Growth Outlook**: AbbVie projects a high single-digit CAGR from 2024 to 2029, with continued EPS expansion and a strong pipeline in immunology, oncology, and neuroscience [25][26] Pipeline and Future Strategies - **Immunology Pipeline**: Focus on B-cell depletion strategies and combination therapies to reset the standard of care in rheumatologic diseases [30][32] - **Neuroscience**: Anticipation of tavapadone approval, which is expected to complement existing therapies and capture significant market share [41] - **Oncology**: Development of antibody-drug conjugates (ADCs) for various cancers, with promising data from ongoing trials [34][38] Financial Outlook - **Investment in R&D**: AbbVie has increased R&D spending significantly, with plans to continue investing in pipeline development [26][28] - **BOTOX**: Continues to be a major asset with a strong market presence, particularly in aesthetics and therapeutics [50] Additional Insights - **Regulatory Strategy**: AbbVie is adapting to new trial policies to enhance efficiency and speed in clinical studies [14] - **Market Positioning**: The company is well-positioned to capitalize on its diverse portfolio and emerging therapies, with a focus on maintaining a competitive edge in the market [52][53] This summary encapsulates the key points discussed during the AbbVie FY Conference, highlighting the company's strategic focus, product developments, and market outlook.

Core Insights - Johnson & Johnson (JNJ) is a significant player in the oncology segment, contributing approximately 27% to total revenues and 42% to the Innovative Medicine segment sales [1] - The company is also strengthening its presence in immunology and neuroscience, which are becoming key contributors to revenue growth outside of oncology [1] Immunology Segment - Sales in the Immunology segment declined by around 12% in 2025 due to the loss of exclusivity of Stelara, which saw a 42% drop in sales [3][8] - Tremfya, another key immunology drug, is partially offsetting this decline, with sales increasing by 41% in 2025, surpassing $5 billion for the first time [3][8] - J&J expects Tremfya to exceed $10 billion in peak-year sales, while Simponi/Simponi Aria sales rose by 22% to $2.7 billion [3][8] - New products and pipeline candidates, such as Imaavy (approved for generalized myasthenia gravis) and Icotyde/icotrokinra (pending approval for plaque psoriasis), are expected to drive long-term growth [4][5] Neuroscience Segment - The Neuroscience segment saw a 10% increase in sales in 2025, driven by new products like Caplyta and Spravato [6][8] - Caplyta generated $700 million in sales, while Spravato recorded $1.7 billion, reflecting a 57% year-over-year increase [6][7][8] - Both Caplyta and other pipeline candidates have the potential to achieve peak sales of $5 billion [7] Overall Growth Strategy - Despite the near-term headwind from Stelara's loss of exclusivity, J&J's expanding immunology portfolio and fast-growing neuroscience franchise are helping to rebalance its growth mix [8][9] - The company is well-positioned for long-term growth with multiple late-stage pipeline candidates in both immunology and neuroscience [9] Competitive Landscape - Key competitors in the immunology space include AbbVie, Eli Lilly, Amgen, Sanofi, and Pfizer [10] - In the neuroscience sector, significant competitors are Biogen, Lilly, and Pfizer [10]

Core Thesis - Celldex Therapeutics, Inc. (CLDX) is positioned as a promising biotech investment for 2026, driven by its advancing immunology pipeline and positive clinical data [3][7]. Pipeline and Product Development - The company has initiated a second Phase III trial for its lead compound, barzolvolimab ("barzo"), targeting chronic inducible urticaria (CIndU), which follows a successful Phase III design for chronic spontaneous urticaria (CSU) [3][4]. - Barzo is described as a "pipeline in a drug," with the potential to target multiple mast cell diseases and achieve premium pricing, with management suggesting that its durable efficacy could support reimbursement comparable to Dupixent's $60,000 annual cost [4][5]. Market Expansion and Indications - Beyond CSU and CIndU, Celldex is preparing to expand into food allergies, leveraging market traction from Novartis' Xolair, and addressing Xolair-refractory patients, enhancing barzo's blockbuster potential [5][6]. - Additional indications for barzo include prurigo nodularis, atopic dermatitis, and chronic urticaria, which further solidify its long-term growth prospects [5]. Additional Products - The company is also developing a second mast cell-targeting monoclonal antibody, CDX-622, which shows promising biological activity and aims to target non-overlapping mast cell populations [6]. Investment Potential - With ongoing pipeline progress, clinical milestones, and the potential for premium pricing, CLDX is seen as an attractive investment opportunity, offering both near-term data readouts and long-term growth potential across multiple indications [7].

Financial Performance - Company reported $1.3 billion in global product net sales for the fourth quarter and $4.2 billion for the full year 2025, representing a 90% year-over-year growth [1][19] - Operating income reached $1.1 billion in 2025, marking the first year of operating profitability [1] - Profit for the year was $1.3 billion, compared to $833 million in 2024, with basic profit per share increasing to $21.08 from $13.92 [20][19] Product Development and Pipeline - VYVGART, the company's leading product, is approved for three indications, including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP) [6][24] - Positive results from the Phase 3 ADAPT OCULUS study support the planned submission for expanding VYVGART's label into ocular myasthenia gravis (oMG) [3][6] - The company aims to treat 50,000 patients globally and secure 10 labeled indications across approved medicines by 2030 [5] Strategic Initiatives - Company is focused on expanding its FcRn portfolio and advancing multiple label expansions, including ongoing registrational studies in rheumatology [4][6] - The expected launch of the VYVGART SC autoinjector in 2027 and the progression of two next-generation FcRn candidates in 2026 are part of the growth strategy [12][26] - The company plans to have four Phase 3 molecules and a total of 10 molecules in clinical development by the end of 2026 [9][26] Market Impact - VYVGART has reached 19,000 patients globally, reinforcing the company's leadership in the myasthenia gravis market [4] - The company is advancing its pipeline with new first-in-class candidates from its Immunology Innovation Program, supporting long-term growth [4][9]

Core Insights - Celldex announced multiple presentations of Phase 2 clinical trials for barzolvolimab at the 2026 AAAAI Annual Meeting, focusing on chronic spontaneous urticaria (CSU), cold urticaria (ColdU), and symptomatic dermographism (SD) [1][2] Group 1: Clinical Trial Presentations - New data from the Phase 2 ColdU and SD Open Label Extension (OLE) will be presented, indicating that retreatment with barzolvolimab results in rapid improvement in urticaria control after symptom recurrence [2] - The presentations include: - **Phase 2 ColdU and SD Study**: "Treatment with Barzolvolimab Improves Urticaria Control and Quality of Life in Patients with Chronic Inducible Urticaria" on February 27, 2026 [2] - **Phase 2 CSU Study**: "Prolonged Off-Treatment Efficacy of Barzolvolimab in Chronic Spontaneous Urticaria" on February 27, 2026 [2] - **Phase 2 ColdU and SD Study**: "Retreatment with Barzolvolimab Leads to Rapid Improvement in Urticaria Control After Symptom Recurrence in Chronic Inducible Urticaria" on March 1, 2026 [2] Group 2: Barzolvolimab Overview - Barzolvolimab is a humanized monoclonal antibody with a novel mechanism of action targeting mast cells by binding to a unique part of the KIT receptor, which is critical for mast cell function and survival [3] - The drug shows significant potential as a first-in-class treatment for CSU, ColdU, and SD, based on data from robust Phase 2 studies [3] - Barzolvolimab is currently undergoing Phase 3 studies for CSU and ColdU/SD, as well as Phase 2 studies for prurigo nodularis (PN) and atopic dermatitis (AD) [3] Group 3: Company Background - Celldex is focused on pioneering new therapies in immunology, particularly antibody-based treatments that engage the human immune system to address allergic, inflammatory, and autoimmune disorders [4]